ImmunoPrecise Antibodies' (IPA) shares climbed by nearly 80% in premarket trading Wednesday after the company said it has developed a new class of GLP-1 therapies to treat diabetes using its LENS AI artificial intelligence platform.
The company said the new therapies were developed through the platform's "rapid sequence generation process."
The new class of GLP-1 therapies are under evaluation for transdermal delivery as a potential alternative to injections, ImmunoPrecise Antibodies said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.